“seattle-genetics” Archives

in
Entry Author Date Location
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More 10/09/20 National
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More 09/25/20 National
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More 09/18/20 National
Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals 09/14/20 Seattle
GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod 08/06/20 National
AstraZeneca to Pay $1B to Team Up With Daiichi Sankyo Again in Cancer 07/27/20 Europe
AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal 06/10/20 National
Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More 05/15/20 National
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More 04/24/20 National
Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod 04/22/20 New York
Seattle Genetics Gets Early FDA Nod for Breast Cancer Combo Drug 04/18/20 Seattle
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal 02/20/20 Seattle
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
SeaGen to Seek FDA Nod After Breast Cancer Drug Hits Goals of Key Study 10/21/19 Seattle
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More 10/01/19 National
Genmab, Mirum Pharma & Fulcrum Raise $653M in Wall Street Debuts 07/18/19 National
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic 10/01/18 San Diego
Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies 03/29/18 Boston
Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks 03/23/18 National
Unum, Homology Plan IPOs, as Unum Reveals Two Patient Deaths 03/05/18 Boston
Bio Roundup: Wilson’s Warning, Amazon’s Health Biz, Moderna Cash & More 02/02/18 National
Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug 01/31/18 Seattle
ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More 12/11/17 National
Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi 11/10/17 National
Bio Roundup: Senate Drama, A.I. Stories, Data Dives, Shkreli & More 06/30/17 National
Bio Roundup: Senate Trumpcare, FDA On Cancer, Alzheimer Review & More 06/23/17 National
SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others 06/19/17 Seattle
Page 1 of 11 next page »